Correlation Between Inozyme Pharma and Enveric Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Enveric Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Enveric Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Enveric Biosciences, you can compare the effects of market volatilities on Inozyme Pharma and Enveric Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Enveric Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Enveric Biosciences.

Diversification Opportunities for Inozyme Pharma and Enveric Biosciences

0.75
  Correlation Coefficient

Poor diversification

The 3 months correlation between Inozyme and Enveric is 0.75. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Enveric Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enveric Biosciences and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Enveric Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enveric Biosciences has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Enveric Biosciences go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Enveric Biosciences

Given the investment horizon of 90 days Inozyme Pharma is expected to generate 0.53 times more return on investment than Enveric Biosciences. However, Inozyme Pharma is 1.88 times less risky than Enveric Biosciences. It trades about 0.05 of its potential returns per unit of risk. Enveric Biosciences is currently generating about -0.01 per unit of risk. If you would invest  141.00  in Inozyme Pharma on September 2, 2024 and sell it today you would earn a total of  130.00  from holding Inozyme Pharma or generate 92.2% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Inozyme Pharma  vs.  Enveric Biosciences

 Performance 
       Timeline  
Inozyme Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Enveric Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enveric Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Inozyme Pharma and Enveric Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inozyme Pharma and Enveric Biosciences

The main advantage of trading using opposite Inozyme Pharma and Enveric Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Enveric Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enveric Biosciences will offset losses from the drop in Enveric Biosciences' long position.
The idea behind Inozyme Pharma and Enveric Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Complementary Tools

Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Equity Valuation
Check real value of public entities based on technical and fundamental data